Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 128 articles: HTML format

Single Articles

March 2026
1. KAI A, Sasada S, Amioka AI, Shigematsu H, et al
   Prognostic Value of Metabolic Parameters on Dedicated Breast Positron Emission Tomography in Luminal Breast Cancer.
   Anticancer Res. 2026;46:1677-1684.
   PubMed     Abstract available
   
   
   
2. JOHANSSON G, Kyriakogiannaki A
   Plan Quality Variability in Radiotherapy of Whole Breast and Regional Lymph Nodes: An Intra-institutional Analysis.
   Anticancer Res. 2026;46:1557-1568.
   PubMed     Abstract available
   
   
   
3. SALMINEN S, Tuomikoski L, Tarkkanen M, Wiklund T, et al
   Evaluation of Radiotherapy Dose in Secondary Breast Angiosarcoma: Implications for Pathogenesis.
   Anticancer Res. 2026;46:1517-1522.
   PubMed     Abstract available
   
   
   
4. WONG A, Narvaez-Rojas AR, Diehl W, Addis D, et al
   Tolerance and Outcomes of Partial Breast Radiation in a Community-based Setting.
   Anticancer Res. 2026;46:1523-1528.
   PubMed     Abstract available
   
   
   February 2026
5. CHECK JH, Check DL, Ganpo-Nkewnkwa N
   Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
   Anticancer Res. 2026;46:1153-1165.
   PubMed     Abstract available
   
   
   
6. DEMIRORS B, Ahmed SH, Grace K, Jimenez PB, et al
   Geographic Variations in Demographics, Socioeconomic Status, and Stage at Diagnosis Among Hormone Receptor-positive Invasive Ductal Carcinoma: An NCDB Analysis (2004-2020).
   Anticancer Res. 2026;46:811-817.
   PubMed     Abstract available
   
   
   
7. SASADA S, Takaya M, Suzuki K, Fujimoto M, et al
   Differences of HER2 Status by HercepTest and PATHWAY 4B5 Immunohistochemical Assays in Breast Cancer.
   Anticancer Res. 2026;46:1123-1130.
   PubMed     Abstract available
   
   
   
8. FUJIOKA S, Kashiwagi S, Kikukawa Y, Watanabe C, et al
   Prognostic Impact of Residual T and N Status After Neoadjuvant Therapy in Breast Cancer.
   Anticancer Res. 2026;46:939-947.
   PubMed     Abstract available
   
   
   
9. GAO S, Yu X, Li Y, Tao L, et al
   Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy.
   Anticancer Res. 2026;46:1037-1052.
   PubMed     Abstract available
   
   
   
10. TAKADA K, Kashiwagi S, Hirata M, Nishikawa M, et al
    Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ.
    Anticancer Res. 2026;46:901-909.
    PubMed     Abstract available
    
    
    
11. SHIRBACHE K, Shirbacheh K, Rezvani A, Shirbacheh A, et al
    Glucose Deprivation of Tumor Cells via Selective Nutrient Delivery: A Potential Therapy for Metastatic Breast Cancer.
    Anticancer Res. 2026;46:589-599.
    PubMed     Abstract available
    
    
    January 2026
12. CHANG CJ, Tung SL, Liao WT, Lay IS, et al
    THEMIS2 as a Novel Mediator of VEGFR2-driven Angiogenesis in Breast Cancer: Functional Suppression by miR-125b-5p.
    Anticancer Res. 2026;46:95-111.
    PubMed     Abstract available
    
    
    
13. GOTO W, Kashiwagi S, Nishikawa M, Watanabe C, et al
    Radiological Complete Response as a Prognostic Marker in HR-positive Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Implications for Treatment De-escalation.
    Anticancer Res. 2026;46:319-325.
    PubMed     Abstract available
    
    
    
14. KINOSHITA H, Kashiwagi S, Nishikawa M, Watanabe C, et al
    Efficacy and Safety of Subcutaneous Pertuzumab-Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan.
    Anticancer Res. 2026;46:293-300.
    PubMed     Abstract available
    
    
    
15. SUWAN N, Teerawongsuwan S, Jenjittikul S, Senaweenin Y, et al
    Andrographolide Induces Mitochondrial Dysfunction and Alters Stemness-related Gene Expression in MCF7 Breast Cancer Cells.
    Anticancer Res. 2026;46:263-272.
    PubMed     Abstract available
    
    
    
16. SUGINO Y, Sakurada H, Baba M, Saito Y, et al
    Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment.
    Anticancer Res. 2026;46:385-394.
    PubMed     Abstract available
    
    
    
17. AL DARWASHI LM, Hajeir MY, Abdelrahman RM, Nordahl EJ, et al
    Efficacy of Magseed Localization for Non-palpable Breast Lesions: A Systematic Review and Meta-analysis.
    Anticancer Res. 2026;46:1-14.
    PubMed     Abstract available
    
    
    
18. MATSUDA H, Goto W, Henmi S, Nishikawa M, et al
    Real-world Outcomes of Postoperative Management for Sentinel Lymph Node-positive Breast Cancer Without Intraoperative Assessment: A Single-institution Retrospective Study.
    Anticancer Res. 2026;46:429-437.
    PubMed     Abstract available
    
    
    
19. HENMI S, Kashiwagi S, Matsuda H, Nishikawa M, et al
    Clinical-Genomic Risk Discordance in Early HR+/HER2- Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX.
    Anticancer Res. 2026;46:439-446.
    PubMed     Abstract available
    
    
    December 2025
20. JANG YS, Jeon SJ, Lee SW, Lee SA, et al
    Piperlongumine Induces Apoptosis and Autophagy via the MAPK/NK-kappaB Pathway in Human Breast Cancer Cells.
    Anticancer Res. 2025;45:5423-5434.
    PubMed     Abstract available
    
    
    
21. MAHMOOD S, Chernov AV, Khan S, Chitteti R, et al
    NSUN7 Suppression Reduces Metastatic Potential and Restores Sensitivity to 4-OH Tamoxifen in Resistant MCF-7 Cells.
    Anticancer Res. 2025;45:5321-5339.
    PubMed     Abstract available
    
    
    
22. KOI Y, Tajiri W, Kawasaki J, Akiyoshi S, et al
    Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR(+)/HER2(-) Metastatic Breast Cancer on CDK4/6 Inhibitor.
    Anticancer Res. 2025;45:5609-5618.
    PubMed     Abstract available
    
    
    
23. USUI T, Shimoda M, Abe K, Masunaga N, et al
    Effect of Tissue Sample Type on The Evaluation of PD-L1 (SP142) Expression in Breast Cancer.
    Anticancer Res. 2025;45:5587-5594.
    PubMed     Abstract available
    
    
    
24. KIM HB, Kim SH, Lee HJ, Park SG, et al
    Down-regulation of ACSM3 Promotes Tumorigenesis in Breast Cancer.
    Anticancer Res. 2025;45:5435-5443.
    PubMed     Abstract available
    
    
    
25. ADMANEGARA PPS, Yulianti R, Rahmawati D, Widiastuti S, et al
    Leveraging Genome-wide Association Studies to Identify Pathogenic Variants for Breast Cancer Among Multiple Continents.
    Anticancer Res. 2025;45:5351-5367.
    PubMed     Abstract available
    
    
    November 2025
26. WOO SH, Lee YH, Jung BC, Kim YS, et al
    Pulsed Electromagnetic Field Promotes Doxorubicin-induced Apoptosis by Increasing Caspase-2 Activation in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2025;45:4921-4931.
    PubMed     Abstract available
    
    
    
27. YANG M, Han J, Won H, Chae SW, et al
    Automated Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Using Deep Learning on Pretreatment Core Needle Biopsy Samples.
    Anticancer Res. 2025;45:5167-5176.
    PubMed     Abstract available
    
    
    
28. HUNG CC, Wang YC, Liu CH, Lin ML, et al
    Impact of Interleukin-12B Genotypes on Breast Cancer Risk.
    Anticancer Res. 2025;45:4771-4781.
    PubMed     Abstract available
    
    
    
29. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    An Investigation of Alexithymia Personality Features Versus Outcome: A Prospective 25-year Follow-up Study in Women With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:5085-5094.
    PubMed     Abstract available
    
    
    October 2025
30. INOUE S, Miki M, Mizumoto S, Yamamoto M, et al
    Immunohistochemical Evaluation of Tumor Characteristic Retention in Triple-negative Breast Cancer PDOX Models.
    Anticancer Res. 2025;45:4169-4180.
    PubMed     Abstract available
    
    
    
31. NAGASHIMA Y, Sasaki K, Nohata K, Chiwaki R, et al
    High Expression of PKCzeta and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2025;45:4357-4372.
    PubMed     Abstract available
    
    
    September 2025
32. AQUINO IG, DE Almeida PC, Rangel-Coelho JP, DE Castro Raucci LMS, et al
    Influence of Caffeic Acid Phenethyl Ester on Osteoblastic Cell Behavior in Coculture With Breast Adenocarcinoma Cells.
    Anticancer Res. 2025;45:3719-3726.
    PubMed     Abstract available
    
    
    
33. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    Psychological Stress Versus Outcome in Patients With Breast Disease and Breast Cancer: A Prospective 25-year Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:3817-3826.
    PubMed     Abstract available
    
    
    
34. LYRONIS G, Efraimidou E, Zachou ME, Kaprana A, et al
    Impact of Fentanyl and Remifentanil on Immune Response in Breast Cancer Patients Post-surgery.
    Anticancer Res. 2025;45:3761-3771.
    PubMed     Abstract available
    
    
    
35. WAGNER JK, Leinhos F, Kunze CA, Bick U, et al
    Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
    Anticancer Res. 2025;45:3749-3760.
    PubMed     Abstract available
    
    
    
36. CIPOLLA C, Gebbia V, DI Stefano V, Messina C, et al
    Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.
    Anticancer Res. 2025;45:4037-4045.
    PubMed     Abstract available
    
    
    
37. SAWA A, Sato R, Matsuo T, Okazaki M, et al
    Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
    Anticancer Res. 2025;45:3827-3833.
    PubMed     Abstract available
    
    
    August 2025
38. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
    Anticancer Res. 2025;45:3479-3486.
    PubMed     Abstract available
    
    
    
39. IIDA K, Iwabuchi E, Miki Y, Hasegawa K, et al
    Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors.
    Anticancer Res. 2025;45:3221-3230.
    PubMed     Abstract available
    
    
    
40. PARK SH, Yoon DH, Kim J, Park SI, et al
    Deletion of the POLR2J4 Gene in Breast Cancer Cells Promotes Bone Metastatic Tumor Growth.
    Anticancer Res. 2025;45:3263-3273.
    PubMed     Abstract available
    
    
    July 2025
41. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed     Abstract available
    
    
    
42. KAMYAN D, Elemam NM, Alkhayyal N, Talaat IM, et al
    Unlocking New Frontiers in Breast Cancer: The Role of the Tumor Microenvironment, Cutting-Edge Therapies, and Immunotherapy.
    Anticancer Res. 2025;45:2729-2747.
    PubMed     Abstract available
    
    
    June 2025
43. IORIO V, Delia P, Solazzo AP, Fazio I, et al
    Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer.
    Anticancer Res. 2025;45:2539-2550.
    PubMed     Abstract available
    
    
    
44. KIM HG, Kang SY, Kim KM, Kim JY, et al
    Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2575-2586.
    PubMed     Abstract available
    
    
    
45. HONG SD, Kang MS, Katuwal NB, Ghosh M, et al
    Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.
    Anticancer Res. 2025;45:2669-2688.
    PubMed     Abstract available
    
    
    
46. LEE IH, Kim EA, Lee SJ, Kang B, et al
    The Role of EMP2 in Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2417-2427.
    PubMed     Abstract available
    
    
    
47. KOKKONEN K, Utriainen M, Penttinen H, Vehmanen L, et al
    Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer.
    Anticancer Res. 2025;45:2605-2618.
    PubMed     Abstract available
    
    
    May 2025
48. RADES D, Bartscht T, Rody A, Yu NY, et al
    Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer.
    Anticancer Res. 2025;45:2123-2135.
    PubMed     Abstract available
    
    
    
49. TAKADA S, Umehara K, Kanae T, Kimura Y, et al
    Prediction of Severe Anemia and Neutropenia Induced by Abemaciclib in Patients With Breast Cancer.
    Anticancer Res. 2025;45:2171-2183.
    PubMed     Abstract available
    
    
    
50. KIM J, Han Q, Kang BM, Mizuta K, et al
    Combination of Recombinant Methioninase With Rapamycin or Chloroquine Is Synergistic to Highly Inhibit Triple-negative Breast Cancer Cells In Vitro.
    Anticancer Res. 2025;45:1853-1859.
    PubMed     Abstract available
    
    
    
51. ZWICKER F, Raether LP, Klepper R, Hauswald H, et al
    Long-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery.
    Anticancer Res. 2025;45:2025-2040.
    PubMed     Abstract available
    
    
    
52. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    The Impact of State-trait Anxiety Inventory (STAI) Self-evaluation versus 25-year Outcome: A Prospective Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:2161-2169.
    PubMed     Abstract available
    
    
    
53. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
    Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
    Anticancer Res. 2025;45:1807-1812.
    PubMed     Abstract available
    
    
    
54. RADES D, Bartscht T, Rody A, Ballegaard M, et al
    Two Scoring Tools to Estimate the Risk of Taxane-induced Peripheral Sensory Neuropathy (PNP) in Patients Irradiated for Non-metastatic Breast Cancer.
    Anticancer Res. 2025;45:2115-2121.
    PubMed     Abstract available
    
    
    April 2025
55. TAKEYAMA H, Manome Y, Koyama M, Yoshii Y, et al
    Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition.
    Anticancer Res. 2025;45:1617-1629.
    PubMed     Abstract available
    
    
    
56. BHALA R, Cando LF, Verma P, Adesoye T, et al
    Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS).
    Anticancer Res. 2025;45:1305-1328.
    PubMed     Abstract available
    
    
    
57. MIKI M, Inubushi S, Han Q, Inoue S, et al
    Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2025;45:1367-1372.
    PubMed     Abstract available
    
    
    
58. FUJII T, Nakazawa Y, Aoki M, Tanabe K, et al
    Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.
    Anticancer Res. 2025;45:1707-1712.
    PubMed     Abstract available
    
    
    March 2025
59. DE SARKAR S, Banerjee S, Ismail A, Mavadia A, et al
    Male Breast Cancer: A Single Institutional Clinicopathological Profiling.
    Anticancer Res. 2025;45:1097-1104.
    PubMed     Abstract available
    
    
    
60. HAQUE W, Verma V, Mangalampalli N, Schwartz MR, et al
    Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.
    Anticancer Res. 2025;45:1055-1061.
    PubMed     Abstract available
    
    
    
61. PARK HJ, Namkung HR, Jung SB, Choi KT, et al
    Anticancer Potential of Black Ginseng Extract in a Breast Cancer Cell Xenograft Mouse Model.
    Anticancer Res. 2025;45:1047-1054.
    PubMed     Abstract available
    
    
    February 2025
62. GOERDT L, Stefanovic A, Wirtz R, Karic U, et al
    Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.
    Anticancer Res. 2025;45:445-450.
    PubMed     Abstract available
    
    
    
63. OSHIRO A, Nagahashi M, Togashi Y, Kanaoka H, et al
    Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.
    Anticancer Res. 2025;45:789-796.
    PubMed     Abstract available
    
    
    
64. YEARBY LA, Kotina M, Ohemeng A, Banjara B, et al
    Noncancerous Exosomes Establish a Growth Promoting Paracrine Effect on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2025;45:419-431.
    PubMed     Abstract available
    
    
    
65. MORINAGA S, Han Q, Mizuta K, Kang BM, et al
    Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.
    Anticancer Res. 2025;45:451-455.
    PubMed     Abstract available
    
    
    
66. SHIN D, Yoo JO, Jeong JH, Han YH, et al
    MiR-5586-5p Suppresses Hypoxia-induced Angiogenesis Through Multiple Targeting of HIF-1alpha, HBEGF and ADAM17 in Breast Cancer.
    Anticancer Res. 2025;45:473-489.
    PubMed     Abstract available
    
    
    January 2025
67. SATO A, Masaka S, Aisaka A, Ishibashi I, et al
    Hederagenin Glycoside Isolated from the Pericarps of Akebia quinata Fruits Induces Apoptotic Cell Death in Breast Cancer Cells.
    Anticancer Res. 2025;45:135-144.
    PubMed     Abstract available
    
    
    
68. SATO A, Yabuki A, Sato G, Nemoto H, et al
    Garlic (Allium sativum L.) Organosulfur Compounds Inhibit Breast Cancer Cell Proliferation by Decreasing Steroid Sulfatase Levels.
    Anticancer Res. 2025;45:145-152.
    PubMed     Abstract available
    
    
    
69. COLLERY P, Desmaele D, Harikrishnan A, Veena V, et al
    Impact of Rhenium(I)-Diselenoether Compound on Cell Adhesion, Migration, Invasion Capacities, and MMP-2 Release in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2025;45:73-79.
    PubMed     Abstract available
    
    
    
70. ZANG M, Zheng J, An X, Li BO, et al
    Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers.
    Anticancer Res. 2025;45:39-53.
    PubMed     Abstract available
    
    
    December 2024
71. SUGANUMA N, Saito N, Yasukawa M, Yamanaka T, et al
    Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.
    Anticancer Res. 2024;44:5187-5192.
    PubMed     Abstract available
    
    
    
72. SUGANUMA N, Matsubara Y, Takahashi A, Yamanaka T, et al
    Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.
    Anticancer Res. 2024;44:5225-5230.
    PubMed     Abstract available
    
    
    
73. OZCIVICI E, Mese G
    Comprehensive Analysis of GJB1 in Breast Cancer: Its Implications in Survival and Molecular Mechanisms.
    Anticancer Res. 2024;44:5379-5391.
    PubMed     Abstract available
    
    
    November 2024
74. QUITMEYER B, Emelife C, Klausner H, Gbayisomore O, et al
    Differential Effects of Punicic Acid on Cytotoxicity and Peroxiredoxin Expression in MCF-7 Breast Cancer and MCF-10A Normal Cells.
    Anticancer Res. 2024;44:4751-4759.
    PubMed     Abstract available
    
    
    
75. GIRO A, Passildas-Jahanmohan J, Kossai M, Bidet Y, et al
    Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study.
    Anticancer Res. 2024;44:4983-4994.
    PubMed     Abstract available
    
    
    
76. CHANTARAAMPORN J, Pothipan P, Sakulterdkiat T, Khiankaew B, et al
    CD47 and Calreticulin Expression in Breast Cancer Subtypes and Anti-CD47 Inhibitory Effects in Macrophage-mediated Phagocytosis.
    Anticancer Res. 2024;44:4929-4940.
    PubMed     Abstract available
    
    
    
77. IKEDA T, Honda CK, Kurozumi S, Yokobori T, et al
    Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis.
    Anticancer Res. 2024;44:4877-4883.
    PubMed     Abstract available
    
    
    
78. GOTO W, Henmi S, Matsuda H, Nakata K, et al
    Predictive Value of Immune Activity Changes in Breast Cancer Patients Treated With Dose-dense Neoadjuvant Chemotherapy: A Retrospective Study.
    Anticancer Res. 2024;44:5123-5129.
    PubMed     Abstract available
    
    
    
79. SEKI H, Ishiguro Y, Makino A, Yamaguchi K, et al
    Nomogram Predicting Axillary Lymph Node Dissection Omission After Neoadjuvant Chemotherapy for Node-positive Breast Cancer.
    Anticancer Res. 2024;44:5131-5138.
    PubMed     Abstract available
    
    
    October 2024
80. AHMED ZM, Abouegylah M, Khedr GA, Eich HT, et al
    Radiation-induced Esophagitis in Breast Cancer Patients Treated With Supraclavicular Field Irradiation.
    Anticancer Res. 2024;44:4543-4549.
    PubMed     Abstract available
    
    
    
81. CHU J, DO SI, Kim HS
    Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis.
    Anticancer Res. 2024;44:4387-4401.
    PubMed     Abstract available
    
    
    
82. UENAKA N, Sato E, Horimoto Y, Kawai S, et al
    CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Anticancer Res. 2024;44:4525-4536.
    PubMed     Abstract available
    
    
    
83. YE Y, Wang J, Dillard J, Barsky SH, et al
    Tumor Dormancy Within the Lymphovascular Embolus Is Regulated by Multiple Metabolism-signaling Pathways.
    Anticancer Res. 2024;44:4165-4173.
    PubMed     Abstract available
    
    
    September 2024
84. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    
85. PALUMBO I, Becchetti AG, Perrucci E, Falcinelli L, et al
    Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects.
    Anticancer Res. 2024;44:3965-3971.
    PubMed     Abstract available
    
    
    
86. YANO T, Ono Y, Yoshimura M, Ono T, et al
    Postoperative Radiotherapy Using VMAT for RNI Including IMN in Breast Cancer: Report of Short-term Follow-up.
    Anticancer Res. 2024;44:4011-4018.
    PubMed     Abstract available
    
    
    
87. UCHIYAMA M, Shima H, Kutomi G, Kyuno D, et al
    Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.
    Anticancer Res. 2024;44:4039-4047.
    PubMed     Abstract available
    
    
    
88. LEE H, Cho YA, Kim DG, Son JY, et al
    Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Anticancer Res. 2024;44:3983-3994.
    PubMed     Abstract available
    
    
    August 2024
89. MAIMON O, Nisman B, Broier S, Ben-David I, et al
    The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.
    Anticancer Res. 2024;44:3543-3550.
    PubMed     Abstract available
    
    
    
90. LIU M, Koo D, Jiang WG, Ye L, et al
    Oestrogen Represses Noggin Expression by Interfering With BMP/Smad Signalling in ER Positive Breast Cancer.
    Anticancer Res. 2024;44:3355-3364.
    PubMed     Abstract available
    
    
    
91. SAHA S, Croyal M, Huvelin JM, Nazih H, et al
    4-Cholesten-3-one Modified the Lipidome of MDA-MB-231 Cells and Potentiated the Effect of Docetaxel.
    Anticancer Res. 2024;44:3277-3285.
    PubMed     Abstract available
    
    
    
92. TANAKA M, Aoki M, Masuda Y, Yoshinaga Y, et al
    Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.
    Anticancer Res. 2024;44:3637-3643.
    PubMed     Abstract available
    
    
    
93. CAROPRESE M, Conson M, Barillaro A, Feoli C, et al
    Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.
    Anticancer Res. 2024;44:3501-3506.
    PubMed     Abstract available
    
    
    
94. NA YM, Park SC, Ryu YJ, Cho JS, et al
    Risk Factors for Non-sentinel Lymph Node Metastasis in HR+/HER2- Breast Cancer With cN0.
    Anticancer Res. 2024;44:3493-3500.
    PubMed     Abstract available
    
    
    
95. MOKBEL K
    Unveiling the Complex Ecosystem of Breast Cancer: Crucial Insights for Patients and Doctors.
    Anticancer Res. 2024;44:3317-3319.
    PubMed     Abstract available
    
    
    
96. CHUNG Y, Chu J, DO SI, Kim HS, et al
    Spatial Transcriptomic Profiling Reveals Gene Expression Characteristics in Lymph Node-positive Breast Carcinoma.
    Anticancer Res. 2024;44:3381-3395.
    PubMed     Abstract available
    
    
    July 2024
97. WOO SH, Jung BC, Kim JY, Lee YH, et al
    PEMF Potentiates Doxorubicin-induced Late G(2) Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2024;44:2837-2846.
    PubMed     Abstract available
    
    
    
98. TAO X, Na LI, Hu EX, Wang J, et al
    Clinical Diagnostic Value of circ-ARHGER28 for Breast Cancer and its Effect on MCF 7 Cell Proliferation and Apoptosis.
    Anticancer Res. 2024;44:2877-2886.
    PubMed     Abstract available
    
    
    
99. HEIDINGER M, Egle D, Piscuoglio S, Navarro-Aguadero MA, et al
    Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Anticancer Res. 2024;44:2981-2988.
    PubMed     Abstract available
    
    
    
100. NIEDER C, Haukland EC, Mannsaker B
     Return to Work After Breast Cancer Treatment: An Electronic Health Record-based Study in North Norway.
     Anticancer Res. 2024;44:3193-3198.
     PubMed     Abstract available
     
     
     June 2024
101. CHU J, DO SI, Kim HS
     Age-related Differences in Spatially Resolved Transcriptomic Profiles of Patients With Hormone Receptor-positive Breast Carcinoma.
     Anticancer Res. 2024;44:2605-2616.
     PubMed     Abstract available
     
     
     
102. WOO SH, Jung BC, Kim JY, Lee YH, et al
     Pulsed Electromagnetic Field Enhances Caffeic Acid Phenethyl Ester-induced Death of MCF-7 Breast Cancer Cells.
     Anticancer Res. 2024;44:2407-2415.
     PubMed     Abstract available
     
     
     
103. CHANG CM, Pekkle Lam HY
     Intratumoral Microbiota: Unraveling their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes.
     Anticancer Res. 2024;44:2271-2285.
     PubMed     Abstract available
     
     
     
104. PIOQUINTO-AVILA E, Gonzalez-Cruz AO, Solis-Estrada J, Hernandez-Juarez J, et al
     Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
     Anticancer Res. 2024;44:2567-2575.
     PubMed     Abstract available
     
     
     
105. GUNNELLINI M, Tornincasa A, Montedoro M, Caprodossi A, et al
     Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success.
     Anticancer Res. 2024;44:2755-2758.
     PubMed     Abstract available
     
     
     
106. MOKBEL K, Mokbel K
     Harnessing Micronutrient Power: Vitamins, Antioxidants and Probiotics in Breast Cancer Prevention.
     Anticancer Res. 2024;44:2287-2295.
     PubMed     Abstract available
     
     
     
107. SUGAWARA-KOMATSU K, Fujii T, Kurozumi S, Ishikawa H, et al
     Significance of MUC1 and beta-Catenin Localization in Mucinous Carcinoma of the Breast.
     Anticancer Res. 2024;44:2689-2698.
     PubMed     Abstract available
     
     
     
108. SUWANNALERT P, Panpinyaporn P, Wantanachaisaeng P, Teeppaibul T, et al
     A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.
     Anticancer Res. 2024;44:2555-2565.
     PubMed     Abstract available
     
     
     
109. RADES D, Janssen S, Narvaez-Wolf CA, Kristiansen C, et al
     Seasonal Impact on Grade >/=2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis.
     Anticancer Res. 2024;44:2617-2620.
     PubMed     Abstract available
     
     
     
110. OMORI S, Ijichi H, Wakasugi A, Shigechi T, et al
     Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients.
     Anticancer Res. 2024;44:2671-2679.
     PubMed     Abstract available
     
     
     
111. AGHIMIEN MO, Kolawole Q, Igbinoba PO, Musa MA, et al
     Non-cytotoxic 3-Acetylcoumarin as an Attractive Target for Human Monoamine Oxidase (HMAO) Enzymes.
     Anticancer Res. 2024;44:2335-2341.
     PubMed     Abstract available
     
     
     May 2024
112. VANNI G, Materazzo M, Lorenzo ND, Tacconi F, et al
     Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride in Non-invasive Axillary Staging in Breast Cancer: Are we Missing a Chance?
     Anticancer Res. 2024;44:2021-2030.
     PubMed     Abstract available
     
     
     
113. GOROBETS O, Keam B, Vinh-Hung V, Nguyen NP, et al
     Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio in De Novo Metastatic Breast Cancer.
     Anticancer Res. 2024;44:1995-2002.
     PubMed     Abstract available
     
     
     
114. CIPOLLA C, Lupo S, Grassi N, Battaglia MC, et al
     The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
     Anticancer Res. 2024;44:2047-2053.
     PubMed     Abstract available
     
     
     
115. PERRONE E, Taralli S, Pagliara D, Larocca LM, et al
     Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After CAR-T Therapy Detected by (18)F-FDG PET/CT.
     Anticancer Res. 2024;44:2243-2245.
     PubMed     Abstract available
     
     
     
116. PSEFTOGAS A, Xanthopoulos K, Siasiaridis A, Poutahidis T, et al
     Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
     Anticancer Res. 2024;44:1885-1894.
     PubMed     Abstract available
     
     
     April 2024
117. SATO M, Han Q, Mori R, Mizuta K, et al
     Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methion
     Anticancer Res. 2024;44:1499-1504.
     PubMed     Abstract available
     
     
     
118. CIMPEAN AM, Comsa S, Sturza A, Barb AC, et al
     Validation of Human Bone Marrow-derived Mesenchymal Stem Cells and MCF-7 Breast Cancer Cells Co-culture Using a 3D Perfused Biomimetic Microfluidic Platform.
     Anticancer Res. 2024;44:1441-1453.
     PubMed     Abstract available
     
     
     
119. KITSUYA N, Matsuoka M, Onodera T, Yokota I, et al
     Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
     Anticancer Res. 2024;44:1591-1601.
     PubMed     Abstract available
     
     
     
120. RADES D, Kristiansen C, Timke C, Duma MN, et al
     Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer.
     Anticancer Res. 2024;44:1525-1531.
     PubMed     Abstract available
     
     
     
121. ARDAVANIS-LOUKERIS G, Kokkali S, Perdikari K, Karatrasoglou E, et al
     A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer.
     Anticancer Res. 2024;44:1559-1565.
     PubMed     Abstract available
     
     
     March 2024
122. SHIN JK, Kim HS, Yoon S
     Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
     Anticancer Res. 2024;44:1051-1062.
     PubMed     Abstract available
     
     
     
123. JANG SY, Kim J, Hong E, Yang YJ, et al
     Phloretin Inhibits the Proliferation of Breast Cancer Cells Through the Down-regulation of Estrogen Receptor alpha.
     Anticancer Res. 2024;44:1109-1120.
     PubMed     Abstract available
     
     
     
124. COLLERY P, Prunier C, Dosda E, Viallet J, et al
     Effectiveness of Rhenium(I)-diselenoether Low Doses in a Triple-negative Breast Cancer Chicken Embryo Model.
     Anticancer Res. 2024;44:941-951.
     PubMed     Abstract available
     
     
     
125. YANG DK, Tungalag T, Lee SJ, Kim SJ, et al
     Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells.
     Anticancer Res. 2024;44:1087-1095.
     PubMed     Abstract available
     
     
     October 2023
126. JUNKINS K, Rodgers M, Phelan SA
     Oleuropein Induces Cytotoxicity and Peroxiredoxin Over-expression in MCF-7 Human Breast Cancer Cells.
     Anticancer Res. 2023;43:4333-4339.
     PubMed     Abstract available
     
     
     
127. CIPOLLA C, Vieni S, D'Agati E, Grassi N, et al
     Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy.
     Anticancer Res. 2023;43:4643-4649.
     PubMed     Abstract available
     
     
     
128. CHOI YE, Sung K, Dong KS, Shin HB, et al
     The Effect of Respiratory Motion in Breast Intensity-modulated Radiation Therapy: 3D-Printed Dynamic Phantom Study.
     Anticancer Res. 2023;43:4425-4433.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum